CLOs on the Move


 
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion
  • www.myriad.com
  • 320 Wakara Way
    Salt Lake City, UT USA 84108
  • Phone: 800.469.7423

Executives

Name Title Contact Details
Jesse Oakeson
Associate General Counsel Profile
Pamela Wong
Executive Vice President and Chief Legal Officer Profile
Justin Hunter
Senior Vice President, Legal Affairs and Corporate Secretary Profile
Justin Hunter
Vice President of Corporate Legal Affairs Profile
Jennifer Fox
Chief Legal Officer Profile

Similar Companies

PsychoGenics, Inc.

PsychoGenics, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Ortho-McNeil Pharmaceutical

Ortho-McNeil Pharmaceutical, Inc. is a Raritan, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Pegasus Laboratories Inc

Pegasus Laboratories Inc is a Pensacola, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IU Health

IU Health is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Artizan Biosciences

Artizan Biosciences, Inc. is a biotechnology company with a mission to restore lives disrupted by inflammatory disease through innovation and advancement of microbiota-targeted therapies. We are leveraging our proprietary IgA-SEQ™ technology platform to distinguish disease-driving bacteria from the intestinal microbiota with the goal of developing new and potentially curative treatments.